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Axon degeneration is an evolutionarily conserved
process that drives the loss of damaged axons and
is an early event in many neurological disorders, so
it is important to identify the molecular constituents
of this poorly understood mechanism. Here, we
demonstrate that the Phr1 E3 ubiquitin ligase is a
central component of this axon degeneration pro-
gram. Loss of Phr1 results in prolonged survival of
severed axons in both the peripheral and central
nervous systems, as well as preservation of
motor and sensory nerve terminals. Phr1 depletion
increases the axonal level of the axon survival mole-
cule nicotinamide mononucleotide adenyltransfer-
ase 2 (NMNAT2), and NMNAT2 is necessary for
Phr1-dependent axon stability. The profound long-
term protection of peripheral and central mammalian
axons following Phr1 deletion suggests that pharma-
cological inhibition of Phr1 functionmay be an attrac-
tive therapeutic candidate for amelioration of axon
loss in neurological disease.
INTRODUCTION
Axon degeneration is a hallmark of many neurological disorders
including neuropathies and neurodegenerative diseases. An
active and evolutionarily conserved mechanism drives axon
loss (Wang and Barres, 2012), so inhibiting this process is an
attractive therapeutic target for treating a wide range of neuro-
logical disorders. Acute severing of axons leads to a process
commonly referred to as Wallerian degeneration, consisting of
axon breakdown, glial and macrophage responses, and clear-
ance of myelin debris (George and Griffin, 1994). Wallerian
degeneration is delayed for at least a week by the ectopic
expression of the Wallerian degeneration slow (WldS) protein,
which acts via a gain-of-function mechanism requiring the
axonal relocalization of its active component nicotinamide
mononucleotide adenylyltransferase, NMNAT1 (Babetto et al.,
2010; Sasaki et al., 2009a). Axon degeneration occurs not only
in response to trauma, but also occurs in metabolic, inflamma-
tory, and hereditary neuropathies as well as neurodegenerative1422 Cell Reports 3, 1422–1429, May 30, 2013 ª2013 The Authorsdiseases (Vargas and Barres, 2007). Remarkably, expression
of WldS or axonal NMNAT can delay axon loss in many of these
disease models suggesting the existence of a general axon loss
program (Wang and Barres, 2012).
While ectopic expression of NMNAT orthologs can delay axon
loss, the endogenous mechanisms that promote axon degener-
ation are largely unknown. Others and we have recently identi-
fied neuron intrinsic pathways that promote axon death (Miller
et al., 2009; Osterloh et al., 2012; Wakatsuki et al., 2011; Wishart
et al., 2012) and have designed screens to identify additional
components (Bhattacharya et al., 2012; Fang et al., 2012; Gerdts
et al., 2011). In a hypomorphic mouse mutant of dual-leucine
zipper kinase (DLK), we demonstrated axon protection for
at least 52 hr after axotomy and identified JNK and SCG10
as downstream signaling effectors (Miller et al., 2009; Shin
et al., 2012). However, only deletion of the sterile alpha- and
armadillo-motif-containing protein (SARM) protein confers
WldS-comparable axon protection in mice for days after periph-
eral nerve transection, yet its mechanism of action remains un-
known (Osterloh et al., 2012). To advance our understanding of
the endogenous processes orchestrating axon death, it is thus
necessary to identify essential components of the degeneration
program and to define the underlying mechanisms.
PHR (PAM-Highwire-Rpm-1) ligases are an evolutionarily
conserved family of large E3 ubiquitin ligases that are central
regulators of multiple aspects of axonal biology. Mutations of
PHR orthologs from worms to mice lead to dramatic defects in
the development of synapses and axons (Bloom et al., 2007;
Culican et al., 2009; D’Souza et al., 2005; Lewcock et al.,
2007; Schaefer et al., 2000; Wan et al., 2000; Zhen et al.,
2000). Recent work in invertebrates demonstrates that PHR
proteins also accelerate the regenerative response following
nerve injury (Nix et al., 2011; Xiong et al., 2010) and delay syn-
apse loss in genetic models of cytoskeletal instability (Massaro
et al., 2009). The involvement of Phr1 (also known as Mycbp2)
in fundamental aspects of axon biology prompted us to test
the role of Phr1 in axon degeneration in mice. Here, we demon-
strate that Phr1 is a central component of the axonal degenera-
tion program. Excision of Phr1 in adult mice leads to long-term
preservation of peripheral nervous system (PNS) and CNS
axons, and Phr1 promotes the self-destruction of injured axons
by limiting the availability of the essential axonal maintenance
factor NMNAT2. This identifies Phr1 as a candidate therapeutic
target for inhibiting axonal loss due to trauma and disease.
RESULTS
Phr1 Deletion Protects Axons and Nerve Terminals
In Vivo
Loss of Phr1 during development in mice impairs axon guidance
and leads to perinatal lethality (Bloom et al., 2007; Lewcock
et al., 2007), so we disrupted Phr1 in young adults using a previ-
ously characterized conditional Phr1 allele (Bloom et al., 2007)
and a tamoxifen-inducible Cre recombinase under the control
of the b-actin promoter (Hayashi and McMahon, 2002). Tamox-
ifen administration induced the excision of the floxed region
within the Phr1 gene (Experimental Procedures), and we
confirmed in vitro that Cre-dependent excision leads to a
decrease in Phr1 protein levels (Figure S1A). Phr1 adult condi-
tional knockout (Phr1 aKO) mice appeared healthy for up to
6 weeks after tamoxifen administration.
In Phr1 aKO mice, we observed profound axon preservation
following injury, comparable to that described in WldS (Mack
et al., 2001) and SARM KO mutants (Osterloh et al., 2012) (Fig-
ures 1A–1D). Axons degenerate about 2 days after sciatic nerve
axotomy in wild-type (WT) mice (Beirowski et al., 2004), with
axons of smaller caliber degenerating faster than large caliber
axons (Vargas and Barres, 2007). In Phr1 aKO mutants, there
is a dramatic delay in loss of both small and large axons, with
75% of myelinated fibers structurally intact 5 days after
axotomy, and 25% of myelinated fibers persisting for at least
10 days (Figures 1A and 1B). Electron microscopy demonstrates
intact axonal organelles and cytoskeleton 10 days after injury
(Figure 1C), as well as persistence of unmyelinated sensory
axons with their associated glia for at least 3 days (Figure 1C).
Biochemical analysis confirms maintenance of cytoskeletal ele-
ments; neurofilament subunits are degraded within 3 days of
injury in WT tibial nerves, but are preserved for at least 10 days
in axotomized Phr1 aKO nerves (Figure 1D). Taken together,
these results show that Phr1 genetic ablation confers a remark-
able delay of axon degeneration in adult mice, protecting small,
large, and unmyelinated sensory axons.
Many debilitating neurodegenerative conditions affect central
axons, so we tested if Phr1 also regulates axon degeneration in
the CNS. We axotomized retinal ganglion neurons, and assayed
axon survival quantitatively in the optic nerve distal to the tran-
section site. Five days after lesion, WT nerves display extensive
axon degeneration with gliosis and axonal replacement by
fibrotic tissue. In contrast, lesioned optic nerves from Phr1
aKO mice appear similar to unlesioned contralateral nerves,
with preservation of the vast majority of axons (Figures 1E–1G).
We next explored whether Phr1 regulates the stability of
terminal specializations such as motor and sensory endings,
which are particularly vulnerable in a variety of neuropathies.
We first assessed the integrity of neuromuscular junctions
(NMJs). In wild-type mice, tibialis anterioris muscles are
completely denervated by 3 days after sciatic nerve axotomy.
In axotomized Phr1 aKO mice, motor nerve terminal degenera-
tion is delayed, with significant numbers of NMJs remaining
occupied (Figures 2A and 2B). We next examined skin sensory
endings, finding an 3-fold increase in the number of intraepi-
dermal fibers (IEPFs) remaining in the Phr1 aKO compared to
WT 3 days after injury (p < 0.05) (Figure S2). Hence, loss ofCPhr1 preserves both axons and their specialized motor and sen-
sory arbors following injury.
Phr1 Loss of Function Protects Neurites
Cell-Autonomously after Disparate Insults
To investigate whether Phr1 KO promotes axon survival in a
neuron-autonomous manner, we cultured embryonic dorsal
root ganglia neurons (DRGs) of Phr1-floxed mice in the absence
of other cell types. We confirmed loss of the neuronal Phr1 pro-
tein after lentivirus transduction ofCre recombinase (Figure S1A).
Distal WT neurites degenerate within 6 hr after transection dis-
playing features such as swelling and fragmentation (Figures
3A and 3B). Axon degeneration is delayed for at least 24 hr
following axotomy in Phr1 KO neurons (Figures 3A and 3B),
demonstrating that Phr1 can act autonomously in the neuron
to control axonal stability. Using this culture model, we next
demonstrated that axonal degeneration induced by the neuro-
toxin vincristine, a chemotherapeutic agent that causes periph-
eral neuropathy, is also delayed in Phr1 KO neurons (Figures
3A and 3B). Thus, Phr1 functions downstream of distinct insults.
Finally, we decreased Phr1 levels using small hairpin RNA
(shRNA) to exclude the possibility that axon preservation is an
allele-specific phenotype. Three independent shRNAs for Phr1
decrease Phr1 protein levels and delay axon degeneration
following axotomy (Figures S1B and S1C). Taken together, these
in vitro studies demonstrate that Phr1 can function cell autono-
mously within neurons to promote axon degeneration induced
by both traumatic and neurotoxic insults. While this in vitro pro-
tection is clear, it is less robust than that conferred by WldS
in vitro even though the in vivo protection in these two mutants
is similar (Babetto et al., 2010). This difference is consistent
with Phr1 having additional axoprotective functions in nonneuro-
nal cells and highlights the importance of in vivo analysis to iden-
tify the most significant axoprotective pathways.
Phr1 Regulates DLK Levels in the Mouse
To investigate the mechanism of action of Phr1, we initially
focused on the MAP3K DLK, which is the best-characterized
target of Phr1-family ubiquitin ligases in invertebrates (Collins
et al., 2006; Nakata et al., 2005; Xiong et al., 2010). While we pre-
viously found no alteration of DLK levels in embryonic Phr1 KO
whole-head lysates (Bloom et al., 2007), here we measured
DLK levels in Phr1 KO DRG cultures and found a 3.9 ± 0.2-fold
increase compared to controls (p < 0.005) (Figure S3A). The dif-
ference between our current findings in DRGs and prior findings
in embryonic head may reflect a cell-type difference or we may
have missed a change in DLK levels in embryonic CNS neurons
because they were masked by expression in nonneuronal cells.
The increase in DLK abundance in the DRG demonstrates that
regulation of DLK levels by PHR ligases is evolutionarily
conserved in invertebrates and vertebrates.
While DLK levels are increased in the Phr1 KO cells, this in-
crease is unlikely to mediate the axoprotective Phr1 KO pheno-
type because loss of DLK, rather than its activation, promotes
axon survival (Miller et al., 2009). To test directly whether
elevated levels of DLK can protect axons, we overexpressed
DLK in cultured DRG neurons. DLK overexpression does not
delay neurite degeneration after axotomy (9 hr after cut, WTell Reports 3, 1422–1429, May 30, 2013 ª2013 The Authors 1423
Figure 1. Phr1 Adult Conditional KO Delays Axon Degeneration in the CNS and PNS
(A) Toluidine-blue-stained cross-sections of axotomized sciatic nerve distal to the cut site, showing delayed axon degeneration in Phr1 adult conditional KO (aKO)
compared to littermate controls (WT).
(B) Quantification of intact myelinated axons of cut and unlesioned contralateral sciatic nerves. Error bars indicate SE.
(C) Electronmicrographs of the nerves shown in (A). Black arrowheads point to preserved small unmyelinated sensory fibers (Remak bundles) in Phr1 aKO nerves.
White arrows point to the preservation of large caliber axons; whose cytoskeleton and organelles remain intact for at least 10 days (inset).
(D) Representative western blot of tibial nerves at the indicated time points after transection, showing preservation of neurofilaments (heavy, NF-H; medium,
NF-M; light, NF-L chains) in Phr1 aKO mice (n = 3).
(E) Toluidine-blue-stained cross-sections of optic nerve distal to the cut site demonstrate almost complete preservation of axons in Phr1 aKO mice 5 days after
eye enucleation, a time point when WT optic nerves are extensively degenerated, as quantified in (G).
(F) Electron micrographs of the same optic nerves shown in (E), demonstrating axon death in WT samples, and morphological axon preservation in Phr1 aKO
samples (insets) 5 days after lesion.
(G) Quantification of intact myelinated axons of cut and unlesioned contralateral optic nerves. Error bars indicate SEM.
See also Figure S1.
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Figure 2. Loss of Phr1 SlowsNeuromuscular Junction Degeneration
(A) Presynaptic motoneuron terminals (antisynaptophysin and antineurofila-
ment M, green) and postsynaptic endplates (bungarotoxin, red) from the
tibialis anterioris muscle remain apposed in Phr1 aKOmice 3 days after sciatic
nerve transection, whereas complete denervation is observed in WT samples,
as quantified in (B). See also Figure S2.
Figure 3. Phr1 Functions within the Neuron to Promote Degenera-
tion in Response to Both Traumatic and Neurotoxic Insults
(A) Phase-contrast images of transected or vincristine-treated neurites are
shown from Phr1 KO or control (WT) embryonic dorsal root ganglia (DRG)
cultures at the indicated time points after injury. The time course of axonal
fragmentation, quantified as degeneration index (see Experimental Pro-
cedures) is shown in (B). Values indicated are the mean ± SE and are repre-
sentative of at least three repeats of each analysis (axotomy and vincristine
treatment). See also Figure S1.degeneration index = 0.51 ± 0.06 SEM; overexpressed DLK
degeneration index = 0.59 ± 0.04 SEM, p > 0.1, n = 3). These
results indicate that Phr1 has a different functionally relevant
target in axons that mediates the change in axon stability.
Phr1 Protects Axons via Increased Levels of the Axonal
Survival Factor NMNAT2
The Phr1 axon protection phenotype in vivo is similar to that
afforded by WldS (Mack et al., 2001), whose active component
is NMNAT1. In mice and humans, there are three isoforms of
NMNATs, and each promotes the survival of axonswhen overex-
pressed (Gilley and Coleman, 2010; Sasaki et al., 2009a; Yahata
et al., 2009). Of these, NMNAT2 is necessary for nerve develop-
ment (Hicks et al., 2012) and behaves as an endogenous axon
survival factor. NMNAT2 is enriched in neurons, is axonally trans-
ported, and has a much shorter half-life than the other NMNAT
isoforms. In vitro loss of NMNAT2 triggers axonal degeneration
and its overexpression delays axon degeneration (Gilley and
Coleman, 2010). Therefore, we tested the hypothesis that Phr1
may limit neuronal NMNAT2 abundance.
The lack of both reliable and sensitive antibodies to
NMNAT2 precluded an assessment of endogenous NMNAT2
levels. Instead, we overexpressed a functional hisMyc-tagged
NMNAT2 in DRG cultures, and found that NMNAT2 levels in
Phr1 KO cultures are 2.0-fold higher (±0.2 SEM, p < 0.05) than
in control cultures (Figure 4A). Analogous experiments with
tagged NMNAT1 and NMNAT3 found no difference in the levels
of these proteins in Phr1 KO neurons compared to control (Fig-
ure S3B). Hence, Phr1-dependent regulation is selective for
the NMNAT isoform with a short half-life and is not a generalCresponse to viral-mediated expression (Figure S3B). Moreover,
endogenous NMNAT2mRNA levels are not significantly different
in Phr1 KO and control neurons (quantitative PCR, p > 0.1),
consistent with posttranscriptional regulation of NMNAT2 by
Phr1. To investigate the subcellular localization of this excess
NMNAT2, we stained Phr1 KO and control cultures expressing
hisMyc-tagged NMNAT2. NMNAT2 is increased in Phr1 KO
neurites (Figures 4B and 4C) but not cell bodies (Figure S3C).
Following injury NMNAT2 protein is rapidly lost from distal axons
as previously described (Gilley and Coleman, 2010), reaching
background levels by 2.5 hr after injury in control axons. In
contrast, Phr1 KO axons maintain higher levels of NMNAT2 after
injury, falling to uncut control levels 5 hr after axotomy (Figures
4B and 4C). Hence, NMNAT2 levels are elevated in Phr1 KO
axons during the commitment phase of axonal degeneration,
the period during which exogenous NMNAT must be present
to block axonal degeneration (Sasaki and Milbrandt, 2010).
The increase in NMNAT2 protein levels in Phr1 KO neurons is
consistent with the Phr1 E3 ubiquitin ligase directly targeting
NMNAT2 for degradation. To test this hypothesis, we assayed
for direct binding between NMNAT2 and Fbxo45, the sub-
strate-recognition subunit of the Phr1 ubiquitin ligase complex
(Wu et al., 2007; Saiga et al., 2009). When coexpressed in
cultured cells, reciprocal coimmunoprecipitation experimentsell Reports 3, 1422–1429, May 30, 2013 ª2013 The Authors 1425
Figure 4. Increased Levels of NMNAT2 Mediates Phr1 KO Protection
(A) Western blot of embryonic DRGs transduced with NMNAT2-hisMyc, showing 2-fold increase of NMNAT2 protein in the Phr1 KO (n = 3).
(B) Representative anti-Myc immunostaining (NMNAT2), counterstained for axons (anti-bIII-tubulin, green), shows NMNAT2 in axons at the indicated time points
after axotomy. NMNAT2 levels decrease after injury in both WT and Phr KO samples, but are consistently higher in Phr1 KO samples, as quantified in (C) (n = 3,
error bars show SE).
(C) Quantification of the anti-myc immunofluorescence intensity (detecting NMNAT2-hisMyc) in neurites at the indicated time points after cut. Error bars showSE.
(D) Coimmunoprecipitation studies from cultured cells demonstrate binding between Fbxo45-Flag, the substrate recognition domain of the Phr1 ligase, and
NMNAT2-hisMyc.
(E) Phase contrast images of uncut and cut DRGs (6 hr after axotomy) showing reversion of the Phr1 KO protection when NMNAT2 is knocked down via shRNA
(shNMNAT2), as quantified in the time course shown in (F).
(F) Quantification of the degree of fragmentation (degeneration index) of Phr1 KO cultures and control, with or without NMNAT2 knockdown, at the indicated time
points after cut. Error bars indicate SEM.
See also Figure S3.demonstrate binding between Fbxo45 and NMNAT2 (Fig-
ure 4D). While this finding is consistent with Phr1 acting as an
ubiquitin ligase to regulate NMNAT2 protein levels, the eventual
loss of NMNAT2 protein from injured Phr1 mutant axons indi-
cates that additional mechanisms must also promote NMNAT2
degradation.
Taken together, these data suggest that loss of Phr1 delays
axonal degeneration by elevating the levels of the axon survival
factor NMNAT2. This model predicts that reducing the levels of
NMNAT2 should revert the axon protection phenotype in the
Phr1 mutant. To test this model, we used lentiviral shRNA
expression to reduce neuronal NMNAT2 transcript levels by
75% as measured by quantitative RT-PCR (not shown). This
partial knockdown of endogenous NMNAT2 does not induce
spontaneous axonal degeneration, and only slightly accelerates
axotomy-induced axonal degeneration in control cultures (Fig-1426 Cell Reports 3, 1422–1429, May 30, 2013 ª2013 The Authorsures 4E and 4F). In contrast, this reduction in NMNAT2 potently
reverts the delay of axonal degeneration following axotomy of
Phr1 KO axons (Figures 4E and 4F). Degeneration is comparable
to control preparations 6 hr after axotomy, and no Phr1-depen-
dent protection is evident 9 hr after axotomy (Figure 4F). These
findings support the model that elevated levels of endogenous
NMNAT2 mediate the axon protection in the Phr1 KO.
DISCUSSION
This study demonstrates a dramatic delay of Wallerian degener-
ation in Phr1 mutant mice. The axon protection is evident in
several neuronal types including myelinated and unmyelinated
axons, central and peripheral nerves, and sensory andmotor ter-
minals. Although there may be differences in the mechanisms of
degeneration in these different neurons (Ebenezer et al., 2007;
Gillingwater and Ribchester, 2001), the broad protection
afforded by the Phr1 KO strongly suggests that Phr1 is a core
regulatory component of a fundamental axon degeneration
mechanism in mammals. Indeed, the axoprotective phenotype
of the Phr1 KO is similar to that of the recently described
SARM1 mutant mice (Osterloh et al., 2012), with preservation
of axotomized peripheral axons for more than a week and
persistence of NMJs for at least 3 days. For Phr1, we have
identified the axon survival protein NMNAT2 as a functional
downstream target. Importantly, we report a regulatory factor
for NMNAT2 in mammals. Modulating the levels of NMNAT2
alters the rate of Wallerian degeneration not only after axotomy
in vitro, but also in mouse models of human tauopathy (Ljung-
berg et al., 2012). Hence, strategies to manipulate NMNAT2
are particularly attractive therapeutic candidates for treating
axonopathies in a broad range of conditions.
Phr1 plays an evolutionarily conserved role in various aspects
of axon biology (Po et al., 2010). Our findings now demonstrate
that PHR proteins play an evolutionarily conserved role in the
control of axonal degeneration. In mutants of the Phr1 ortholog
highwire in Drosophila, motor nerve terminals are protected
from genetic disruption of the cytoskeleton (Massaro et al.,
2009). In addition, a recent study in Drosophila showed that
Highwire promotes axon degeneration by limiting the levels of
the Drosophila NMNAT enzyme (Xiong et al., 2012). Hence,
PHR regulation of axonal degeneration via control of NMNAT
isoform levels is an evolutionary conserved component of a pro-
gram that likely balances axonal maintenance and degeneration.
How does Phr1/Highwire regulate NMNAT2 and Drosophila
NMNAT? Phr1 is an E3 ubiquitin ligase that can ubiquitinate
and degrade targets (Han et al., 2008) and we show here that
NMNAT2 binds to Fbxo45, the substrate recognition domain of
the Phr1 ubiquitin ligase complex. In addition, NMNAT2 and
Drosophila NMNAT accumulate after MG132-mediated inhibi-
tion of degradative pathways, so NMNAT2 is likely regulated
via the ubiquitin proteasome system (Gilley and Coleman,
2010; Xiong et al., 2012). However, others and we have yet to
detect ubiquitination of NMNAT2 (Xiong et al., 2012), raising
the possibility of additional regulatory mechanisms.
The extent of Phr1 aKO protection is similar to that of the gain-
of-function WldS mutant (Mack et al., 2001). In the Wlds mutant
the axoprotective NMNAT1 enzyme is mistargeted to axons
and functionally compensates for the loss of NMNAT2 after
injury. However, in contrast to the chimeric WldS protein, which
is a gain-of-function mutation, Phr1 is an endogenous protein
that limits the levels of NMNAT2 and promotes axonal degener-
ation. Two interesting questions arise from this finding. First, how
do increased levels of NMNAT2 protect axons when the protein
is still rapidly lost within hours of injury? This is an issue both in
the Phr1 mutant and when NMNAT2 is overexpressed in wild-
type neurons. Indeed, overexpression of NMNAT2 in wild-type
neurons leads to long-term protection but the protein is unde-
tectable within a few hours after injury (Figure 4; Gilley and
Coleman, 2010). Elevated levels of NMNAT2 may have a unique
function in the first hours after injury, or low levels of residual
protein may still function long after the injury. In the Phr1 KO,
additional targets may also contribute to axonal protection.
Second, why do neurons have a mechanism to restrict the levelsCof an axoprotective molecule such as NMNAT2? Short-lived ax-
oprotective molecules are maintained in the axon by constant
replenishment via anterograde axonal transport, and so their
presence in the axon can serve as a signal of a healthy connec-
tion with the cell body (Gilley and Coleman, 2010; Shin et al.,
2012). Axons that are not well connected can therefore be rapidly
and efficiently eliminated, reducing the possibility of damaging
adjacent axons, and clearing the way for regeneration. Such a
mechanism would require molecules such as Phr1 to regulate
the levels of axoprotective factors such as NMNAT2.
In conclusion, we have identified Phr1 as a key regulator of a
core axon degeneration program that balances axon survival
and loss in various neuronal cell types. The profound long-term
protection of injured mammalian axons following deletion of
Phr1 suggests that pharmacological inhibition of Phr1 function
could be an attractive therapeutic strategy for ameliorating
axon loss in neurological diseases in which axonopathy is a
major component, such as peripheral neuropathies, glaucoma,
multiple sclerosis, and some neurodegenerative diseases (Var-
gas and Barres, 2007). The great challenge will be in designing
specific inhibitors of the Phr1 ubiquitin ligase, as efforts to target
ubiquitin ligases are in their infancy (Zhao and Sun, 2012).
EXPERIMENTAL PROCEDURES
Mouse Dorsal Root Ganglia Cultures
Spot DRG cultures were described previously (Shin et al., 2012). E13.5 Phr1
floxed-allele (Bloom et al., 2007) or CD1 (Charles River) DRGs were cultured
with 1 mM 5-fluoro-20-deoxyuridine and 1 mM uridine (Sigma) to block non-
neuronal cell division. To avoid confounding effects from somatic death, at
2 days in vitro (DIV) DRGswere transducedwith Bcl-XL lentivirus, which blocks
apoptosis but not injury-induced degeneration (Vohra et al., 2010). Cre recom-
binase (KO) or FCIV (WT) were introduced via lentiviral transduction in Phr1-
floxed DRGs from the same preparation at DIV 2–4. ShNMNAT2, or shControl,
was applied at DIV 4 to avoid complete NMNAT2 knockdown and subsequent
spontaneous axon degeneration. ShPhr1, or DLK overexpressing lentiviruses
were applied to CD1 DRGs at DIV 2. See Extended Experimental Procedures
for details of constructs. At DIV 8–9, after complete neurite development, cul-
tures were lysed, axotomized, or treated with vincristine as per the specific
experiment, and neurite degeneration were analyzed as described (Sasaki
et al., 2009b).
Ultrastructural Studies
For assessing optic axon survival mice were perfused transcardially (ice-cold
3% glutaraldehyde [Polysciences] in 0.1 M phosphate buffer). Sciatic nerves
and optic nerve segments distal to the axotomy site were harvested, and the
first millimeter was discarded. See Extended Experimental Procedures for
production of semithin sections and ultrathin sections. From these sections,
a blinded investigator quantified intact axons 5 mm distally from the axotomy
site by established methods (Beirowski et al., 2009, 2011; Marina et al., 2010).
Western Blot
Immunoprecipitated material (obtained as described in the Extended Experi-
mental Procedures) and DRGswere lysed in Laemmli buffer. Snap-frozen tibial
nerves were homogenized in RIPA buffer with protease inhibitor tablet
(cOmpleteMini EDTA-free, Roche). Western blot was performedwith standard
protocols. Antibodies are listed in the Extended Experimental Procedures.
Intensities of protein bands were normalized by comparison with the loading
control (bIII-tubulin or GAPDH).
Immunocytochemistry
Immunostaining was carried out on glass slides (BD Falcon) as described (Shin
et al., 2012). Neurons were stained for NMNAT2-hisMyc using anti-Mycell Reports 3, 1422–1429, May 30, 2013 ª2013 The Authors 1427
antibody (9B11, Cell Signaling, 1:500) and counterstained for bIII-tubulin (TUJ,
Aves lab, 1:500), with the appropriate Alexa-conjugated secondary antibodies
(Invitrogen). Confocal stacks were obtained with a Nikon D-Eclipse C1
confocal microscope and z-projected. The axonal NMNAT2 level was
assessed with ImageJ. Images were thresholded for bIII-tubulin immunoreac-
tivity to define the axonal area, and the average anti-Myc immunofluorescence
intensity was measured within the defined area and background was
subtracted.
Mouse Husbandry and Surgery
Phr1-floxed mice (Bloom et al., 2007) were bred to B6.Cg-Tg(CAG-cre/Esr1*)
5Amc/J mice (Jackson lab) that express a tamoxifen-inducible Cre-recombi-
nase. Tamoxifen (Sigma) was injected intraperitoneally (0.1 mg/g) to all litter-
mates, including those without theCre allele (wild-type, WT), for 2 consecutive
days for 3 weeks starting at 60–80 days of age. Surgical axotomy is described
in the Extended Experimental Procedures. At the indicated times, mice were
euthanized, or intracardially perfused, and tissue was dissected. To test for
Cre recombination, a small portion of the tail tip was collected before tamox-
ifen injection, and DRGs were dissected at the endpoint of the experiment.
PCR analysis (Bloom et al., 2007) verified the appearance of a recombina-
tion-specific band in DRGs from mice expressing Cre. Mouse handling and
surgery were supervised by the Division of Comparative Medicine of the
Washington University in Saint Louis.
Neuromuscular Junction Staining and Quantification
Surgery was performed 2 weeks after the first tamoxifen injection. Tibialis
anteriormuscleswere collected frommice intracardially perfused (4%parafor-
maldehyde in 0.1 M PBS) and postfixed for 2 hr at room temperature. Cryo-
preservation, cryosectioning of 60-mm-thick sections, and staining procedures
were performed as described (Babetto et al., 2010; Extended Experimental
Procedures). For morphological NMJ quantification, endplate occupancy
was assessed by a masked investigator. Full and partial occupancy was
defined as a state when the postsynaptic bungarotoxin labeling was com-
pletely or partially opposed by the axon terminal. Fifty to 100 NMJs were quan-
tified for each muscle preparation, from three mice per genotype.
Statistical Analysis
A Student’s t test or ANOVA, with Tukey post-hoc, was used to test statistical
significance. The p values > 0.05 were considered not significant. Data are
presented as mean ± SEM.
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